Share Name Share Symbol Market Type Share ISIN Share Description
CVS Group LSE:CVSG London Ordinary Share GB00B2863827 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +1.00p +0.10% 1,031.00p 1,032.00p 1,036.00p 1,040.00p 1,015.00p 1,016.00p 165,894 16:35:29
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Retailers 271.8 14.5 18.5 55.7 661.48

CVS Group Share Discussion Threads

Showing 426 to 448 of 450 messages
Chat Pages: 18  17  16  15  14  13  12  11  10  9  8  7  Older
DateSubjectAuthorDiscuss
17/1/2018
20:55
Not really, this is in a similar format to the November 2016 comment. They have not historically given Revenue/Profit numbers until the formal half year trading statement, which last year was not until 31 March. To release an update so soon after the end of the half year to 31 December, I would not have expected these numbers.IMO these guidance is positive, given the market reaction to the November 2017 update I suspect they were keen to provide an update sooner rather than later. The timing is unusual, perhaps they thought that the market would have more time to to digest the update if they released it when they did.
lomax99
17/1/2018
20:30
Very odd time of day to release a trading update, epsecially for a 'positive' one. No mention of revenue or EBITA or market expectations, as they've had in previous trading statements. I wonder what brokers will make of it.
typo56
17/1/2018
20:09
Positive trading update, released after market close.
lomax99
13/1/2018
19:00
Peel Hunt re-iterates a 1350p target. Not carrying much weight, but MF fancies CVSG for a recovery: Https://www.fool.co.uk/investing/2018/01/13/2-turnaround-stocks-id-buy-in-2018/
lomax99
11/1/2018
18:38
Thanks, seems about right. Looks like it's settling down a bit with a lovely neat £10 closing price. Hopefully a steady move back up. You're right, institutions keep adding, albeit in smallish amounts.
stun12
10/1/2018
19:52
Hi Stun, No the article was around the time of the posting, and the Directors holding was announced on 8 December. Institutions have been increasing recently, it looks oversold.
lomax99
10/1/2018
16:50
Hi lomax. Is that article quite old? Just that it's add recommendation is at 915p, a level last reached ahortly after the figures came out. Also, can't see the Chairman's purchase...similarly dated? Bought some at just over and just under £10 as it seems to motor once it gets going, mostly on the downside at the moment. Just looking for a quick 10% or so.
stun12
08/12/2017
07:55
Good to see the Chairman pick up £91.1k worth of shares. Latest IC comment: CVS pays the price for high expectations The annual general meeting of veterinary group CVS (CVSG) is usually an opportunity for management to proudly reveal that recent acquisitions have sent profits way ahead of expectations. Normally, what proceeds is a flurry of broker upgrades and a stampede to buy the shares. Not so this time around. News that like-for-like revenue growth has slowed to 4.3 per cent wiped 30 per cent off the group’s share price in three days. The price has been paid for high expectations. To a certain extent, the drop in organic revenue growth can be explained by the extraordinarily strong performance last year: in the four months to September 2016, revenues grew 6.3 per cent on a like-for-like basis. But management has also pointed to a slowdown in the UK veterinary marketplace, which they think may have been caused by economic instability, and a drop in the number of clinicians. Moreover, exclude the Animed Direct online veterinary retail division – which reported a 60 per cent increase in sales – and the underlying business only grew 1.5 per cent in the first four months of the financial year, compared with 6.3 per cent in the year to June 2017. And yet overall revenue growth remains just as spectacular as ever at 20.6 per cent. The group spent £20m on 21 new surgeries in the period, taking the total number of sites up to 444 (from 378 in the comparable period last year). Those acquisitions span the UK – from north Scotland to south Wales – and cover domestic animals, farm animals and horses. Four new sites have been added in Northern Ireland and three in the Netherlands, including the first Dutch equine business. But the price of veterinary practices has climbed to roughly 10 times adjusted cash profits, according to brokers at Peel Hunt, compared with the historic range of six to eight times. CVS has spent £6.5m more in the first four months of the current financial year than last, for just three more surgeries. But there are positives. More expensive surgeries mean more willing sellers and CVS maintains the financial firepower to keep growing via acquisition: net debt is forecast to fall to just 1.7 times adjusted cash profits by the end of June 2018 thanks to the group’s ability to generate cash. IC View The recent turn of events will have been disappointing for followers of our buy tip. However, we also think the sell-off is a major over-reaction to moderately disappointing news. With the shares now trading on 17 times forward earnings, we think this is an ideal opportunity for investors to top up their holdings. Buy at 915p.
lomax99
07/12/2017
12:19
Interest from MARS would not be that left field: Https://www.bloomberg.com/news/articles/2017-01-09/mars-expands-in-pet-care-with-9-1-billion-deal-for-vca
lomax99
07/12/2017
12:16
Well I've held on so far lol
hydrus
07/12/2017
12:13
CVS Group: hero to villain - time to buy? http://bit.ly/2AziwJA Big research note, covers cash flow, revised forecasts and market position
investorschampion
07/12/2017
12:12
It may take time, and there may be pullbacks on the way, but this re-rating has quite some way to go.....
lomax99
07/12/2017
10:05
intra bounce
luckymouse
07/12/2017
08:12
Shares magazine: Sales growth slowdown triggers CVS share slump Staffing issues and consumer uncertainty blamed for weak trading update One of AIM’s most successful stocks has experienced a rare moment of share price weakness. Veterinary services provider CVS (CVSG:AIM) has fallen by 30% in value to 900p in the past week after a slowdown in sales growth, blamed on uncertain economic conditions troubling consumers and a shortage of clinicians in the UK. It says salaries will now be increased by more than inflation, plus more flexible working hours, in order to attract more veterinary surgeons to work for the company. It will fund these extra costs by putting up its prices. CVS achieved 4.3% like-for-like sales growth for the four months to 31 October, a slowdown from the levels seen in financial years 2016 and 2017. Stripping out high growth but lower margin online drugs arm Animed Direct, CVS’s like-for-like growth was a muted 1.5%. This news has soured CVS’s long run of making money for its shareholders. It had generated 680% total return (share price appreciation plus dividends) in the five years to the eve of its troublesome trading update on 30 November. The business has historically generated strong cash flows and rising dividends thanks to operating in an industry more resilient than most, since UK animal lovers prioritise spending on the wellbeing of their pets. While the near-term outlook is less certain, Berenberg reiterates its ‘buy’ rating and £14.50 price target, implying 60% upside over the next 12 months. The investment bank flags easier year-on-year comparative figures across the rest of the financial year to June 2018, meaning ‘like-for-like growth should accelerate in the second half’. It still forecasts robust 4.8% like-for-like growth this year. CVS itself says customer loyalty remains high with its healthy pet scheme memberships exhibiting ‘excellent growth’ and providing earnings with some backbone. Berenberg notes CVS is making strong progress on acquisitions in the UK and Netherlands with its pipeline of deals remaining strong. It adds: ‘CVS has made further acquisitions in the equine market, where it envisages significant medium-term opportunities given the lack of consolidation and less competition for assets from its main competitors for acquisitions like Independent Vetcare.’ Among the risks to its bullish investment thesis is competition for practices; any increased competition for assets would raise the multiples CVS has to pay on M&A, ‘decreasing the earnings accretion it currently enjoys on acquisitions’. For the year to June 2018, Berenberg forecasts £315m revenue (2017: £272m) and £38m pre-tax profit, ahead of £335m and £42m respectively in 2019. On forecast earnings of 46.6p, rising to 51.2p in 2019, CVS’s sharp de-rating leaves the shares selling for less than 20 times forward earnings. (JC) ------------------------------------- At last nights close the PE's implied are 18.4 and 16.7. The YE 2019 fee growth forecast is somewhat pessimistic, with revenues only climbing £20M/6.3% - bearing in mind they attributed £65.1M of the uplift in YE 30/6/17 revenues to acquisitions, this assumes acquisitions almost come to a halt, can't quite see this myself.
lomax99
06/12/2017
21:24
There was strong selling from 1500 but then a quick but brief bounce from 1300 before the big drop. I agree it looks like a determined seller but that has got a lot of PIs spooked and selling. We were all buying a company we recognised as quality but if that quality isn't recognised any more it starts to look expensive. I was also concerned by the recent RNS which seemed designed to push the price down.I'm out and not sure what price level I will decide is worth buying back in. It's about when everybody else thinks there is value.
ewanwhose
06/12/2017
21:07
I do wonder if a fund is Panic selling as can't really understand why it's gone so low. It's not that far off having halved from peak.
hydrus
06/12/2017
19:15
Dechra moving in tandem so it seems.
r ball
06/12/2017
17:28
Yes interesting parallel with GBG alphabet. I have a lot but bought more on dip This drop seems rather overdone! Glad I sold a couple of weeks ago but looking to get back in...
gswredland
06/12/2017
16:27
High PE stocks getting punished...
jak1
06/12/2017
12:11
CVSG looking weak again - I might have to exit if it goes too low and accept the small loss as a penalty for not completing my research first. Haven't had to chance to mull it over properly yet hence the initial small stake.
hydrus
06/12/2017
10:47
You might be right Alpha, I am also in GB group. I already had a decent holding in CVSG, and I am adding, as it drops, in progressively larger amounts.
lomax99
06/12/2017
10:39
I held these until recently and was intrigued when I saw the drop on the statement. It reminds me of GBG around October last year - a growth share on a chunky pe where a small miss led to c42% off the price, same here equates to 862p. I know it sounds harsh but there must have been a number of fearful distressed sellers here, which IMHO is the ideal situation to be buying in. There was a considerable rebound there (see below) so I couldn't resist a buy at just over £9. https://uk.advfn.com/p.php?pid=chartscreenshot&u=VZJtIZdGsd8q6mZdTBvcefaUo%2Bo%2FYevKbCRHl2eVvJI%3D&kslash=s
alphabeta4
06/12/2017
10:11
Added again in the 860's.
lomax99
Chat Pages: 18  17  16  15  14  13  12  11  10  9  8  7  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20180118 02:06:16